TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dandan, Yang, Xuexian O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156211/
https://www.ncbi.nlm.nih.gov/pubmed/32205092
http://dx.doi.org/10.1016/j.jmii.2020.03.005
Descripción
Sumario:COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Ejemplares similares